Bicycle Therapeutics Investor Relations Material

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycle molecules. These molecules are fully synthetic short peptides constrained by small molecule scaffolds, forming two loops that stabilize their structure. This design allows them to bind to targets with high affinity and selectivity, making them promising candidates for drug development, particularly in areas where existing therapeutics are lacking. Bicycle Therapeutics is headquartered in Cambridge, UK, with significant operations in Cambridge, Massachusetts. Its shares are listed on NASDAQ.